The device is inherently automated -- it's diabetes without the numbers," said study senior author Edward Damiano, an associate professor in the department of biomedical engineering at Boston University.
understands the issue more keenly than most, as he
is the father of a 15-year-old son with type 1 diabetes.
said the device "exceeded our expectations, reducing average [blood-sugar levels] to what's well below standard-care therapy, while at the same time reducing [low blood-sugar levels]."
said that, within 18 months, he
hopes to have one integrated machine containing an insulin reservoir, a glucagon reservoir, a continuous glucose monitor receiver and the computer program.
In the meantime, the researchers will continue to work on the fully integrated device, and hope to start clinical trials on that in 18 months or so, according to Damiano
Both Damiano and Russell
believe they'll have their device ready to market in fewer than five years.
is hoping for no longer than 39 months -- that's when his
son will head off to college.
SOURCES: Edward Damiano, Ph.D., associate professor, biomedical engineering, Boston University; Steven Russell, M.D., Ph.D., assistant professor, medicine, Massachusetts General Hospital, Boston; Aaron Kowalski, vice president of artificial pancreas research for JDRF (formerly the Juvenile Diabetes Research Foundation); June 15, 2014, New England Journal of Medicine, online; June 15, 2014, presentation, American Diabetes Association annual meeting, San Francisco